olaparib targets prostate cancer mutations Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer. Phosphate-binder therapy does not reduce mortality ...

Newark, NJ, May 30, 2022 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, The global feed binder market is expected to grow from USD 5.10 billion in 2019 to USD 6.58 billion by 2027, ...

Please provide your email address to receive an email when new articles are posted on . Vifor Pharma's Phase III study on its hyperphosphatemia treatment in chronic kidney disease patients has been ...

FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with ...